Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022
Research

Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany

Johanna Erber, Verena Kappler, Bernhard Haller, Hrvoje Mijočević, Ana Galhoz, Clarissa Prazeres da Costa, Friedemann Gebhardt, Natalia Graf, Dieter Hoffmann, Markus Thaler, Elke Lorenz, Hedwig Roggendorf, Florian Kohlmayer, Andreas Henkel, Michael P. Menden, Jürgen Ruland, Christoph D. Spinner, Ulrike Protzer1, Percy Knolle1, Paul Lingor1Comments to Author , and on behalf of the SeCoMRI Study Group2
Author affiliations: University Hospital rechts der Isar, Munich, Germany (J. Erber, V. Kappler, B. Haller, H. Mijočević, C. Prazeres da Costa, F. Gebhardt, N. Graf, D. Hoffmann, M. Thaler, H. Roggendorf, F. Kohlmayer, A. Henkel, J. Ruland, C.D. Spinner, U. Protzer, P. Knolle, P. Lingor); German Center for Infection Research, Munich (J. Erber, D. Hoffmann, J. Ruland, U. Protzer, C.D. Spinner); Helmholtz Zentrum München-German, Neuherberg, Germany (A. Galhoz, M.P. Menden); Ludwig-Maximilians University Munich, Martinsried, Germany (A. Galhoz, M.P. Menden); German Center for Diabetes Research, Neuherberg (M.P. Menden); Technical University of Munich, Munich (M.P. Menden)

Main Article

Table 2

SARS-CoV-2 seroprevalence for healthcare workers, by self-reported risk factors and symptoms, at a university hospital, Munich, Germany*

Characteristic No. SARS-CoV-2 IgG positive/no. with data available (%)
 Odds ratio (95%CI) No. SARS-CoV-2 IgG positive/no. with data missing
True False
Individual risk factors
Pulmonary disease 8/317 (2.5) 99/4,212 (2.4) 1.1 (0.48–2.14) 1/25
Cardiovascular disease 5/329 (1.5) 102/4,200 (2.4) 0.64 (0.22–1.43) 1/25
Diabetes mellitus 5/79 (6.3) 102/4,451 (2.3) 2.96 (1.01–6.81) 1/24
Immunodeficiency 0/92 (0.0) 107/4,434 (2.4) 1/28
Immunosuppressive therapy 1/69 (1.4) 105/4,461 (2.4) 0.7 (0.03–3.15) 2/24
Smoking
 11/817 (1.3)
 96/3,718 (2.6)
 0.52 (0.26–0.94)
 1/19
Exposure
Patient facing role 55/2559 (2.1) 50/1,934 (2.6) 0.83 (0.56–1.22) 3/61
AGPs 9/712 (1.3) 96/3,794 (2.5) 0.50 (0.23–0.94) 3/48
COVID-19 assigned unit 21/712 (2.9) 85/3,803 (2.2) 1.34 (0.80–2.13) 2/39
Emergency department 11/515 (2.1) 95/3,999 (2.4) 0.91 (0.46–1.64) 2/40
Ward 43/1633 (2.6) 63/2,882 (2.2) 1.21 (0.81–1.79) 2/39
Intensive care unit
 16/690 (2.3)
 89/3,824 (2.3)
 1.00 (0.56–1.67)
 3/40
Contact with SARS-CoV-2‒positive person
Patient 31/1028 (3.0) 74/3436 (2.2) 1.42 (0.91–2.15) 3/90
Co-worker 29/816 (3.6) 76/3644 (2.1) 1.74 (1.11–2.65) 3/94
Private contact 22/220 (10.0) 83/4218 (2.0) 5.56 (3.32–8.94) 3/116
Unprotected contact 34/435 (7.8) 70/3997 (1.8) 4.77 (3.09–7.22) 4/122
Protected contact
 32/1230 (2.6)
 73/3237 (2.3)
 1.16 (0.75–1.75)
 3/87
Personal protective equipment
Use of PPE 104/4458 (2.3) 2/75 (2.7) 0.81 (0.25–5.35) 2/21
Surgical mask 104/4437 (2.3) 2/95 (2.1) 1.04 (0.32–6.83) 2/22
FFP2/N95-mask 32/1497 (2.1) 74/3011 (2.5) 0.87 (0.56–1.31) 2/46
FFP3-mask 8/325 (2.5) 96/4163 (2.3) 1.09 (0.48–2.13) 4/66
Protective clothing 34/1677 (2.0) 72/2835 (2.5) 0.8 (0.52–1.19) 2/42
Eye protection or face shield
 29/1580 (1.8)
 77/2934 (2.6)
 0.7 (0.45–1.06)
 2/40
Symptoms
Experienced symptoms 79/1272 (6.2) 28/3263 (0.9) 7.62 (4.98–12.00) 1/19
Exhaustion 54/771 (7.0) 53/3763 (1.4) 5.27 (3.57–7.78) 1/20
Fatigue 67/795 (8.4) 40/3738 (1.1) 8.49 (5.72–12.77) 1/21
Cough 50/668 (7.5) 57/3861 (1.5) 5.40 (3.65–7.97) 1/25
Shortness of breath 19/307 (6.2) 88/4222 (2.1) 3.12 (1.82–5.08) 1/25
Rhinitis 47/689 (6.8) 60/3843 (1.6) 4.62 (3.11–6.82) 1/22
Loss of smell 36/144 (25.0) 71/4384 (1.6) 20.23 (12.87–31.41) 1/26
Loss of taste 39/124 (31.5) 67/4402 (1.5) 29.62 (18.79–46.38) 2/28
Sore throat 30/740 (4.1) 77/3792 (2.0) 2.05 (1.31–3.11) 1/22
Headache 46/766 (6.0) 61/3766 (1.6) 3.88 (2.61–5.73) 1/22
Limb pain 36/403 (8.9) 71/4129 (1.7) 5.61 (3.67–8.45) 1/22
Shivering 36/442 (8.1) 71/4092 (1.7) 5.03 (3.29–7.56) 1/20
Diarrhea 20/316 (6.3) 87/4214 (2.1) 3.22 (1.90–5.21) 1/24
Increased temperature 46/491 (9.4) 61/4032 (1.5) 6.73 (4.51–9.98) 1/31
Fever, temperature >38°C 29/233 (12.4) 77/4288 (1.8) 7.79 (4.90–12.1) 2/33

*AGP, aerosol-generating procedure, COVID-19, coronavirus disease; FFP, filtering face piece; PPE¸ personal protective equipment, SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Main Article

1These authors contributed equally to this article.

2Members of the SeCOMRI study group are listed at the end of this article.

Page created: December 15, 2021
Page updated: February 21, 2022
Page reviewed: February 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external